Eisai Inc. and Helsinn Group today announced the Food and Drug Administration (FDA) approval of Aloxi (palonosetron hydrochloride) injection for the prevention of acute nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including highly emetogenic cancer chemotherapy, in children aged 1 month to less than 17 years.  This is the first approval of a product for acute chemotherapy-induced nausea and vomiting (CINV) prevention in patients aged 1 month to 6 months.  The age of peak cancer incidence among children occurs within the first year of life, so this approval offers an important option to children, and especially infants, undergoing chemotherapy.

For more details, go to: http://www.reuters.com/article/2014/05/28/nj-eisai-fda-approval-idUSnPn6XBcZd+9a+PRN20140528